Adalimumab-800CW + Fluorescence Imaging for inflammatory bowel diseases

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 6 May 2019: Trial registered, NCT03938701
  2. 6 Aug 2024: Trial started, NCT03938701

The trials

NCT03938701: Fluorescence Imaging of IBD and RA Using Adalimumab-800CW

State
Under way
Phase
Phase 2
People
36 planned
Started
6 Aug 2024
Primary completion
Mar 2026
Arms
1. Fluorescence imaging of inflammatory bowel disease and rheumatoid arthritis with adalimumab-800CW, 2. Fluorescence imaging of inflammatory bowel disease and rheumatoid arthritis with adalimumab-800CW, 3. Fluorescence imaging of inflammatory bowel disease and rheumatoid arthritis with adalimumab-800CW
Results
None posted
  1. 6 May 2019: Trial registered
  2. 6 Aug 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.